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Genital Ureaplasma is a worldwide issue in obstetrics and gynecology.  Morbidities 
can include pelvic inflammatory disease, infertility, miscarriage, preterm delivery, and 
chorioamnionitis, if left untreated. The quality improvement (QI) initiative used a 
retrospective chart review of 128 subjects, collecting data of antibiotic treatment differences 
and recurrence of genital Ureaplasma at a corporate owned obstetrical and gynecologic 
outpatient clinic in the metro-Denver area. The investigator used the percentage change 
mathematical formula to determine the percentage difference between patient antibiotic 
treatment only with symptomatic genital Ureasplasma versus antibiotic treatment of the 
patient and the partner. Overall, the project did not show statistical difference between the 
two variables (percentage change of 14.47%). However, unintentional findings were reported 
on the recurrence difference between patient and patient and partner treatment between the 
antibiotics doxycycline (20.7% and 16.57%), azithromycin (50.07% and 50.7%), and 
clindamycin (100% recurrence rate with and without partner treatment). The major limitation 
of this project was the small sample size. The most significant implication of this project was 
that the antibiotic findings were consistent with CDC and UpToDate guidelines. It appeared 
that doxycycline has a higher success rate for treatment of genital Ureaplasma. Further 
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Symptomatic genital Ureaplasma is an emerging concern in gynecology. With potential risks 
of untreated symptomatic genital Ureaplasma including pelvic inflammatory disease, 
infertility, miscarriage, preterm delivery, and chorioamnionitis, it is imperative that provider 
education with a review of CDC guidelines are explored starting at the clinical level. The 
PICO statement the project sought to address was whether women with symptomatic genital 
Ureaplasma have a decreased incidence of symptomatic recurrence when both the patient 
and the partner are treated with antibiotic therapy than treatment of the patient alone.  
Purpose 
This capstone project which was a quality improvement (QI) initiative, investigated if there 
was a difference in the incidence of symptomatic recurrence of genital Ureaplasma in the 
female patient when treating the patient and partner as compared to treating the patient alone 
with antibiotic therapy. 
Goals 
The primary goal of the project was to determine whether the relationship between antibiotic 
treatment differences and recurrence of symptomatic genital Ureaplasma was statistically 
significant. A secondary goal was to explore the recommendations of evidenced-based 
guidelines related to urethritis and cervicitis caused by Ureaplasm 
Objective 
The objective of this quality improvement initiative was to conduct a retrospective chart 
review of the antibiotic treatment differences of patient and partner treatment versus patient 
only treatment for genital Ureaplasma within a corporate owned obstetrics and gynecology 
office in the metro-Denver area  
Plan 
In planning the project, a data collection tool was created and approved by the QI project site 
administrator to identify the diagnosis for the visit using ICD-10 codes as identifiers, positive 
PCR testing for genital Ureaplasma, antibiotic treatment (doxycycline, azithromycin, or 
other), partner treatment, test of cure results, and recurrence of symptoms resulting in a return 
visit in a 3-month period of time. A priori sampling size of 128 was calculated using the 
G*Power software (Department of Psychology, 2019) with the alpha of 0.05 and power of 
0.80. The investigator used a percentage change mathematical formula to determine the 
percentage difference between the two scores. The inferential statistic used was Kendall’s 
tau.  
Outcomes and Results 
The project did not show statistical difference between the two variables (percentage change 
of 14.47%). However, unintentional findings were reported on the recurrence difference 
between patient and patient and partner treatment between the antibiotics doxycycline (20.7% 
and 16.57%), azithromycin (50.07% and 50.7%), and clindamycin (100% recurrence rate 
with and without partner treatment). The unintentional findings are consistent with CDC and 
UpToDate guidelines. It appeared that doxycycline has a higher success rate for treatment of 
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Considerations of Antibiotic Treatment for Genital Ureaplasma 
 Symptomatic genital Ureaplasma is a world-wide issue in obstetrics and gynecology. 
A single study performed at a multicenter/multicultural laboratory concluded 47.3% (n=833) 
of the female participants sampled tested positive for genital Ureaplasma when the patient 
presented with clinical symptoms of vaginitis (Leli, et al., 2018).  This exposure rate is 
consistent with other studies.  With potential risks of untreated symptomatic genital 
Ureaplasma including pelvic inflammatory disease, infertility, miscarriage, preterm delivery, 
and chorioamnionitis, it is imperative that education starting at the clinical level is explored. 
This quality improvement (QI) initiative was a retrospective chart review of the antibiotic 
treatment differences and recurrence of genital Ureaplasma at a corporate owned obstetrical 
and gynecologic outpatient clinic in the metro-Denver area. This paper includes a description 
of the practice problem with an articulated review of supporting literature and evidenced 
based practice guidelines. The paper also presents a market/risk analysis for conducting the 
project, the project objectives and methodology and evaluation plan, as well as an analysis of 
project findings and results and a discussion of limitations, recommendations and 
implications for change. 
Problem Recognition and Definition 
Project Purpose 
The purpose of this capstone project, which is a quality improvement (QI) initiative, 
was to investigate if there is a statistical difference in the incidence of symptomatic 
recurrence of genital Ureaplasmas in the female patient when treating the patient and partner 
as compared to treating the patient alone with antibiotic therapy.  The primary investigator 
used a retrospective chart review to identify symptoms of genital Ureaplasma and antibiotic 
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treatment, to determine if the female patient alone or the patient and partner were treated for 
Ureaplasma, and measured rates of symptomatic recurrence of genital Ureaplasma in the 
intervention and the comparison groups.  
Problem Statement  
The problem statement for the proposed project was as follows: Lack of treatment of 
partners who test positive for Ureaplasma may increase sexual transmission of this 
microorganism.  The problem statement for the capstone project was identified when the 
primary investigator recognized the antibiotic treatment differences, in women with positive 
Ureaplasma culture, between 13 providers in an obstetric and gynecologic clinic in the metro-
Denver area. The primary investigator suspected that treatment inconsistencies among 
providers were due to the lack of knowledge of genital Ureaplasma signs, symptoms, and 
negative effects, as well as preferred antibiotic treatment options. The primary investigator 
and another seasoned nurse practitioner became concerned with the number of female 
patients that returned to the clinic with recurrent symptoms of genital Ureaplasma.   
The risks of genital Ureaplasma if left untreated in symptomatic patients, is known to 
lead to pelvic inflammatory disease (PID), ectopic pregnancy, infertility by blocking 
fallopian tubes, and recurrent vaginosis in the non-pregnant female. In a pregnant patient, 
Ureaplasma can lead to preterm rupture of membranes and preterm labor/delivery (Diaz, et 
al., 2013). 
The Center for Disease Control (2015) guidelines recommend antibiotic treatment for 
male urethritis and female cervicitis. Genital Ureaplasma falls into this category. With the 
aforementioned risk of genital Ureaplasma, it is important for clinicians to provide antibiotic 
treatment in a timely manner.  
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PICO 
The capstone project utilized the “PICO” question format rather than a formal 
research hypothesis. The PICO acronym stands for: Population or Patient (P), Intervention 
(I), Comparative Intervention (C), and Outcome (O) (Houser & Oman, 2011). The question 
the project sought to address was: Do women with symptomatic genital Ureaplasmas have a 
decreased incidence of symptomatic recurrence when both the patient and the partner are 
treated with antibiotic therapy than treatment of the patient alone?  
In the PICO format, the question reads:  
P (patient): Women with symptomatic genital Ureaplasmas 
I (Intervention): Treating patient and partner with antibiotic therapy 
C (comparison): Treating the patient alone 
O (outcome): Decrease the incidence of symptomatic recurrence 
Project Significance, Scope, and Rationale 
Genital Ureaplasma species have gained more attention as being an attributing 
bacterium associated with adverse effects to the health of men, women, and neonates. In 
women, genital Ureaplasma can cause pelvic inflammatory disease (PID), leading to potential 
ectopic pregnancy or infertility. According to the CDC (2017), an estimated 2.5 million 
women aged 18–44 years in the United States reported a history of PID diagnosis within their 
lifetime. This quality improvement project may have a financial impact by decreasing the rate 
of PID seen in a clinical setting, as well as decreasing cost of potential adverse effects from 
the Ureaplasma species.  
The scope of this project was a quality improvement project internal to a large 
obstetrics and gynecology clinic in the metropolitan Denver area. This study was not meant 
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to develop new knowledge or to be generalized outside of the agency where the QI project 
took place.  
The rationale for the project was to inform providers within the practice of antibiotic 
treatment for genital Ureaplasma. The investigator identified the capstone project with DNP 
Essential II: Organizational and Systems Leadership for Quality Improvement and Systems 
Thinking (AACN, 2006). This project focused on the direct care of patients who had 
symptomatic Ureaplasma and their partners. It provided the investigator with an opportunity 
to apply evidence-based guidelines/policies that could potentially improve the quality of 
health care for this population. 
Foundational Theory  
The investigator used two theories for the theoretical framework for the capstone 
project, which were the Neuman Systems Model and Lewin’s Theory of Change.   
Betty Neuman (1924-2008), introduced her Neuman Systems Model in 1970 while 
she was a professor at UCLA. Her background in nursing included Community and Mental 
Public Health. “The goal of the model was to provide a holistic overview of the 
physiological, psychological, sociocultural, and developmental aspects of human beings” 
(“Betty Neuman”, 2010). The theory developed over time with adaptability for use in the 
classroom, community, and clinical practice. The purpose of the Neuman Systems Model is 
viewing the patient, or client as termed by Dr. Neuman in her theory, as an open system that 
reacts to stressors.  Stressors may include environmental, psychological, developmental, 
physiological, and spiritual sources.  
One of the major concepts of the model was identifying the client as having “rings” 
representing each component of the model. The inner “ring” is the central circle, which is the 
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basic vital signs, genetics, strengths and weakness of the system (client).  The next ring is the 
line of resistance. This protects the client from outside factors/stressors and maintains a 
healthy system.  The next ring is the flexible line of defense, which serves as a protective 
buffer to prevent stressors from invading the client (Ume-Nwagbo et al., 2006).  This line is 
seen as being fluid and can move away or towards the line of resistance. The normal line of 
defense completes the Neuman Systems Model and is thought to be developed over time as 
the system learns coping mechanisms, as well as outside influences and beliefs.  
The Neuman Systems model is a middle-range theory that can be applied to the 
Capstone problem statement: As a nurse or provider, their function is to assess an 
individual’s reaction to a stressor (as in this case, symptoms consistent with genital 
Ureaplasma) has on the system (or the patient).  The primary care provider can use primary 
(education), secondary or preventative measures (antibiotic treatment to patient and partner), 
and tertiary measures (management/treatment of recurrent symptoms) to return the client to 
health and stability. See Appendix A for The Neuman Systems Model. 
Kurt Lewin (1890-1947) was a German-American social psychologist.  Lewin’s 
Change Theory consists of three levels: unfreezing, changing/transition, and refreezing.  The 
unfreezing stage begins after the problem or the needs for change is identified. In unfreezing, 
“physicians and staff must be motivated to change by means of exposure to new ideas and 
creating a sense of urgency around the shared vision of how patient care outcomes and the 
work environment could be enhanced by the proposed change” (Stichler, 2011, p. 9).  During 
the unfreezing stage, in this case, providers must be prepared for change by treatment of 
patient and partner in light of positive Ureaplasma. The transition or moving phase consists 
of a plan of action that is developed to engage “people to try out the proposed change” 
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(Shirey, 2013, p. 70).  The last phase, the refreezing stage, consists of acceptance of change 
into routine practice. Lewin’s model is found to be versatile, simple to implement, and easy 
to understand (Shirey, 2013).  
Applying Lewin’s Change Theory in context with the problem statement, the problem 
was identified within one OB/Gyn practice where providers are treating women with positive 
genital Ureaplasma inconsistently. Patients returning to the clinic with recurrent symptoms of 
genital Ureaplasma promoted the Unfreezing phase.  The Transition phase may evolve over 
time during the Capstone project, depending on the results of the study and recommendations 
made by this investigator. Refreezing or acceptance of a different way of treating the patient 
and partner may occur if the results point to a change in routine practice of managing 
Ureaplasma infections (see Appendix B for Lewin’s Theory of Change model).  
Literature Selection/Systematic Process 
A systematic review of the literature was conducted using CINAHL, Google Scholar, 
PubMed, Ovid, and Sage databases between the dates of September 2018 through September 
2019. The search was limited to articles dated after 2009 and publications in English 
language, but were from several countries including Italy, India, Brazil, Switzerland, and the 
United States. Exclusion criteria included articles more than 7 years old, written in language 
other than English, focus on pregnancy, and pediatrics. Keywords for the literature review 
included: Genital Ureaplasma, Ureaplasma parvum, Ureaplasma urealyticum, real-time PCR, 
antibiotic susceptibility, vaginal discharge, Mycoplasmas, asymptomatic infection, NGU, 
cervicitis, urethritis, diagnosis, management, and partner treatment. By using a combination 
of the keywords, the investigator found 50 articles that was later narrowed to 30 articles 
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pertaining to the project. In addition, the investigator selected information from the Centers 
for Disease Control and Prevention as well as UpToDate. 
Scope of Evidence 
There were several types of studies used in the literature, including: quasi-
experimental, systematic review, retrospective analysis, experimental, and correlational. 
Melnyk and Fineout-Overhalt’s (2015) table was used to identify the level of evidence using 
four of seven levels for the 30 articles and are identified as follows:  
• Level I- systematic review or meta-analysis of randomized control trials- 11 articles, 
• Level II- evidence from one or more randomized control trials- 3 articles, 
• Level III- controlled trial with no randomization- 12 articles, and 
• Level IV- case controlled or cohort studies- 4 articles. 
Background of Problem  
Ureaplasma is considered a normal flora residing in the respiratory and urogenital 
tract of humans. According to Saigal, Dhawan, Rawre, Khanna, and Chaundry (2016), 
approximately 60-80% of sexually active women have been exposed to genital Ureaplasma 
before they are 40 years old, and remain asymptomatic in both developed and developing 
countries. Symptomatic Ureaplasma are bacteria known to cause adverse effects in men, 
women, and neonates. 
Combaz-Sochnchen and Kuhn (2017) found limited literature regarding women and 
urogenital Ureaplasma. The authors noted women experiencing chronic urinary tract 
symptoms, including urethritis, overactive bladder, and interstitial cystitis, should be tested 
by PCR assay for Ureaplasma spp. 
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After the investigator conducted a search for applicable research articles related to the 
PICO question, a systematic review of evidence table was created (see Appendix C for an 
example).  Emerging themes from the search resulted in five categories: biology and 
transmission of genital Ureaplasmas, urethritis and cervicitis, microbiology of diagnosis and 
detection, antibiotic susceptibility, and clinical guidelines.  
Review of Evidence 
Systematic Review of the Literature 
Biology and transmission of genital Ureaplasmas.  Genital Ureaplasma belong in 
the smallest, free-living self-replicating organisms of Mollicutes, and can also be found in the 
general category of genital Mycoplasmas (Kokkoyail & Dhawan, 2015). There are two 
known genital biovars, those being Ureaplasma urealyticum (Biovar 1) and Ureaplasma 
parvum (Biovar 2). Together, these biovars identified under the category of Ureaplasma 
species (spp.). For the purpose of the project, the investigator did not differentiate findings 
into the two biovars, but as Ureaplasma species.  
Ureaplasma spp. is transmitted by direct host contact including genital to genital, 
genital to oral, as well as vertical transmission (mother to fetus), or by transplanted tissue 
(Waites & Bronze, 2019). Genital Ureaplasma is not considered a sexually transmitted 
infection since it is found as a normal flora in humans.  
In transmission from male to female partner, men “act as asymptomatic carriers and 
function as reservoirs and vectors" (Silva, Cerqueira, Teixeira, Bicho, Campainha, Amorin, & 
Medeiros, 2018, p. 1003). Ureaplasma pathogens may be introduced into a healthy vagina 
through intercourse causing lysis of healthy Lactobacillus. 
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Neonates who are colonized with Ureaplasma are presumably exposed during a 
vaginal delivery, since colonization is less common in infants born via cesarean section 
(Baum, 2018). In this case, Mycoplasmas (Mycoplasma and Ureaplasma spp.) adhere to 
mucosal epithelial cells of the respiratory tract. It can disseminate to other sites when there is 
a disruption of the mucosa or an underlying immunity of the host, in this instance, the 
neonate (Baum, 2018).   
Urethritis and cervicitis. Symptoms of urethritis or cervicitis are what often prompts 
the patient to seek medical care. Clinical complaints for women are abnormal vaginal 
discharge, pelvic pain, vaginal burning, dyspareunia, and abnormal uterine bleeding (Centers 
for Disease Control and Prevention, 2015). The CDC (2015) defines the symptoms of males 
and females as experiencing dysuria, urethral pruritus, and mucoid, mucopurulent, or 
purulent discharge. 
Co-infections can be seen in the presence of genital Ureaplasma. Ureaplasma will 
thrive in a favorable pH environment, with better survival rate in the symbiotic relationship 
with anaerobic bacterial vaginosis (Rumyantseva, et al., 2018).  Frolund et al. (2019) found 
bacterial vaginosis is often present in Ureaplasma positive samples speculating that 
production of urea from Ureaplasma increases vaginal pH, which in turn leads to an increased 
bacterial load of bacterial vaginosis.  
The prevalence of genital Ureaplasma spp. suggest sexually active adults should be 
screened for these pathogens and condoms should be promoted. "Though coinfections were 
not associated with increase in severity of clinical manifestations, however, these infections 
could be transmitted to their partners contributing to clinical morbidity" (Saiga, Dhawan, 
Rawre, Khanna, Chaudhry, 2016, p. 195).  If left untreated, symptomatic Ureaplasma spp. are 
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associated with pelvic inflammatory disease (PID) and infertility. Obstetric complications 
include chorioamnionitis, spontaneous abortion/miscarriage, stillbirth, and premature rupture 
of membranes (Verteramo, Patella, Calzolari, Recine, Marcone, Osborn, & Degener, 2013). 
Microbiology of diagnosis and detection.  The incubation period of genital 
Ureaplasmas is approximately 10-20 days (Kimberlin, Brady, & Jackson, 2018). 
Symptomatic genital Ureaplasma on exam and microscopically may include mucopurulent 
discharge, first void urine with >10 WBC's on high power field of microscopic assessment, 
and gram staining of >2WBC's per oil immersion field. Symptomatic cervicitis characteristics 
include a purulent or mucopurulent discharge visible to the examiner in the endocervical 
canal or on an endocervical swab specimen and a friable cervix or bleeding of the endocervix 
when touched with a cervical swab (Liu, Cao, Zhao, Zhao, & Huang, 2014). 
Since Mollicutes lack a cell wall, the organism cannot be visualized by Gram stain. 
Nucleic-acid amplification tests (NAAT), including PCR and DNA chip assay, are used for 
detection of Mycoplasmas (Baum, 2018).  Polymerase chain reaction (PCR) is the test of 
choice when testing for Ureaplasma due to affordability and timeliness of results. PCR 
testing is collected from the urethra or endocervix with a polyester or nylon tipped swab, 
which is then placed in the liquid transport material for laboratory assessment. 
Antibiotic susceptibility. Four classes of antibiotics are recognized for treatment of 
urogenital Ureaplasma: fluoroquinolones, tetracycline, chloramphenicol, and macrolide 
classes (Beeton, & Spiller, 2016). Based on CDC (2015) guidelines, the first-line treatment is 
azithromycin 1gram or doxycycline 100mg/day for 7 days. In the United States, doxycycline 
is available with high antibiotic susceptibility rate at 76%, whereas ciprofloxacin showed 
resistance to Ureaplasma at 82% (Kasprzykowska, et al., 2017). Other susceptible antibiotics 
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to Ureaplasma available in the U.S. are minocycline with 74.7% susceptibility and 
clindamycin with 74% susceptibility. Diaz, et al., (2015) found a high resistance against 
fluoroquinolones due to their overuse for treatment of urinary tract infections and upper 
respiratory infections. The number of therapeutic options are limited in pregnancy and 
neonates’ due to the accumulation of tetracycline in developing bones.  During pregnancy, 
azithromycin 1gram for a single dose is preferred. Erythromycin can also be administered 
with a 42% susceptibility rate. (Al-Khadfaji, 2017).  
Clinical guidelines and recommendations. Initiating treatment of Ureaplasma spp. 
infection is imperative to prevent occurrences of potential future complications. There are 
inconsistent partner treatment guidelines found between countries, without any substantial 
empirical data to inform treatment decision (Ong, et al., 2017). The recommendations in the 
United States for treatment of Ureaplasma is found through the CDC.  For treatment of non-
gonococcal urethritis or cervicitis, the Centers for Disease Control and Prevention currently 
recommends azithromycin, 1g orally in a single dose or doxycycline, 100mg twice a day for 
7 days (Terris & Kim, 2018).  This recommendation reflects all genital pathogens and is not 
exclusive to Ureaplasma spp.  
Waites and Bronze (2019) states “successful treatment hinges on promptly 
considering Mycoplasma and Ureaplasma species as potential etiologic agents, performing 
proper diagnostic tests for their detection, and providing appropriate antimicrobial coverage" 
(p. 8). Ureaplasma spp. are opportunistic organisms that may be present simultaneously with 
other pathogens, such as bacterial vaginosis. Treatment decisions should reflect this. 
The literature review supported the investigator’s PICO question of antibiotic 
treatment options and provides guidelines on treating both partners for symptomatic genital 
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Ureaplasma. With risk factors of untreated Ureaplasma, including infertility in women at 21-
32%, pregnancy risks, and PID, it is important to consider proper antibiotic treatment 
(Tandon, Munne, Chauhan, & Patil, 2019).  By providing a quality initiative, supported by 
the literature, the project may increase provider knowledge at the obstetric/gynecologic 
practice site for the capstone project.   
Market Risk Analysis 
SWOT Analysis 
 To perform an analysis of the market where the capstone project was completed, a 
SWOT Analysis was conducted identifying the Strengths, Weaknesses, Opportunities, and 
Threats (See Appendix D).  There were a number of strengths identified for this project, 
including evidenced based practice and guidelines as reviewed in the systematic review of 
literature. Nucleic Acid Amplification Tests (NAAT) are readily available in the clinical 
setting, and there was clinical support from providers for a quality initiative project.  
 The investigator identified weaknesses to the project as well. One of the hurdles 
encountered was the investigator was no longer employed at the site the capstone project was 
to take place. This led to early written approval of a letter of intent submitted to the health 
care corporation for review.  The site is now a midwife only practice; however, they are able 
to provide obstetrical and gynecologic care at the capstone site. Another weakness identified 
was potential resistance to change provider practice of treatment of genital Ureaplasma. The 
final weakness identified was data collection being limited to one area located in the metro-
Denver area.  
 The project allowed for recognition and staff development opportunity to providers in 
the clinical site by providing an evidenced based literature review and guidelines, as well as 
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acknowledging an easily identified microorganism through NAAT collection to prevent 
future obstetrical and gynecologic morbidities.  This can decrease the overall cost to health 
insurance companies and the patient by providing early detection and treatment, rather than 
the costliness of such morbidities such as PID.  
 There were three threats identified to the project.  The first threat is the current 
unstable state of the corporate run clinic that was dismantled within a 6-week period, laying 
off two physicians and 4 nurse practitioners, and closing two of the three locations. This also 
led to the second threat of the current office being short-staffed, therefore, all remaining 
providers may not be able to attend the QI presentation due to days off and call schedule.  
This may result in providers continuing to practice with inconsistent treatment measures.  
The final threat was COVID-19, which delayed collection of the data due to the reduction of 
work hours for both the biller printing out the patients fitting the ICD-10 parameters, as well 
as the clinical mentor collecting the data.  
Driving and Restraining Forces 
 The driving force behind the capstone project was the rate of recurrent vaginal 
infections, intermenstrual bleeding, and pelvic pain that was seen when Ureaplasma was 
positively identified on NAAT.  The investigator began to notice a pattern of antibiotic 
treatment of the patient versus treatment of the patient and the partner. Associated cost with 
the return office visits was also a driving force for the project. At this time, the PICO 
question was formed and the QI was developed in order to increase staff knowledge of 
symptoms associated with Ureaplasma, testing method, antibiotic susceptibility, and 
guidelines.  
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 One of the restraining forces noted by the investigator was possible lack of provider 
knowledge of providers on Ureaplasma treatment guidelines. This may lead into a second 
restraining force of resistance to change their practice, even with evidence supported by the 
literature review. A third restraining force was lack of time in the providers schedule for the 
investigator to present the findings to the group during a single session. The presentation may 
have to take place on the provider’s day off, which the provider may not agree to attend the 
presentation.  
Needs, Resources and Sustainability 
Needs.  The need for the capstone project was first identified in the clinic setting by 
the investigator and another nurse practitioner within in the clinic, with a combined 
experience as advanced nurse practitioners of 50 years. As testing for genital Ureaplasma 
became widely available, pathologists from Metropolitan Pathologists would attend “lunch 
and learn” sessions educating the available clinicians on the collection process for genital 
Ureaplasma, reporting sheets, and treatment options. Not all clinicians attended the sessions, 
while other clinics within the practice did not desire a pathologist to discuss any new testing 
options. In time, the two experienced nurse practitioners noticed treatment differences 
between clinicians as patients returned to the clinic for recurrent vaginitis symptoms.  The 
investigator began looking into available treatment guidelines, which was reviewed in the 
literature review.  
Due to the prevalence of recurrent genital Ureaplasma symptoms and inconsistent 
antibiotic treatment, there was a need to implement an educational intervention for clinicians 
within the practice.  
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 Resources. The resources needed to complete the project were minimal. NAAT 
testing through PCR, including through NuSwab and Thinprep, are available at no cost to the 
clinic or patient. Personnel used for the project included the Capstone Chair, clinical mentor, 
HCA contract administrator and security officer, and investigator. The clinical mentor 
collected data for the project during her time away from work and had agreed to assist in the 
project free of cost. The electronic medical record (EMR) system, Electronic Clinical Works, 
is already used nationally through the HCA system. See Appendix E for the cost to replicate 
the study.  
Sustainability.  A sustaining force the investigator planned on implementing was an 
evidenced-based practice guideline for the chosen clinic based on project findings, as well as 
existing guidelines from the CDC. In order to accomplish this, the investigator used a Power 
Point Presentation to educate the providers on guidelines and findings. The investigator also 
included laboratory testing that was readily available (NAAT testing through ThinPrep and 
NuSwab) to the provider that already exists in the clinical setting as well as the appointed 
laboratory used (LabCorp).  
Feasibility/Risks/Unintended Consequences 
 Feasibility.  The implementation of the evidence-based project was feasible at HCA 
Mountain Vista Midwifery due to the former connection the investigator had as an employee 
for several years at the mentioned site.  The investigator maintained a positive relationship 
with the management team, as well as the providers when exiting the practice. The 
availability of the existing positive standing between the investigator and mentor and the 
resources available, made this capstone project feasible. 
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Risks.  There was no risk of harm to human subjects or animals with this quality 
improvement (QI) project.  The project only collected information that was recorded in the 
electronic health record and was given to the investigator by the mentor using aggregated 
data. The consent was waived, as the waiver will not adversely affect the rights and/or 
welfare of the subjects. The intention of this QI project was to explore best practice for 
consistency in antibiotic treatment in patients with positive genital Ureaplasma on genital 
culture to promote health of the patient.  
Unintended Consequences.  The investigator did not have control of the antibiotic that 
was prescribed to patients by other providers in the clinic. The investigator also had no 
control of whether the patient or patient and partner was compliant and completed the course 
of antibiotic therapy prescribed. Other unintended consequences are discussed later in this 
paper under findings.  
Stakeholders and Project Team 
 The stakeholders that benefited from the capstone project included the health 
corporation that owns the clinic used for the project, providers, patients, their partners, and 
the community.  The investigator discussed the plan via email for this project with the 
stakeholders/health corporation (see Appendix F, Letter of Intent) and worked closely with 
the HCA contracts coordinator to obtain site approval for conducting the project.  
 The project team included the Regis University faculty project chair, the Regis 
University DNP student (investigator), and the capstone clinical mentor.  
Cost-Benefit Analysis 
A retrospective data analysis was used, and therefore, data was readily available at no 
cost to the investigator.  Charts were readily available to the clinical mentor who assisted in 
CONSIDERATIONS OF ANTIBIOTIC TREATMENT 17 
 
gathering data for compliance with HIPAA. The clinical mentor agreed to review patient 
charts on her time away from the work place. 
The cost that was incurred for the patient who is seen in the clinic for symptoms of 
vaginitis, pelvic pain, dyspareunia, and intermenstrual bleeding, and/or history of Ureaplasma 
was charged a co-payment, which usually ranges from $2.00-$50.00. The insurance is billed 
a CPT charge at a 99203 (new patient with a detailed history, detailed exam, and low 
complexity decision making) or 99213 (existing patient with a detailed history, detailed 
exam, and low complexity decision making).  The reimbursement from a 99203 and 99213 
visit is $109.46 and $72.70 (E/M University, 2017).  The transport media used through 
LabCorp was free of charge to the clinic. The cost of running the testing for genital 
Ureaplasma and Mycoplasma is $122.75 through LabCorp.  The out of pocket cost of oral 
doxycycline 100mg twice a day for 7 days is $7.68-$14.17 when using the GoodRx phone 
application (2019). For the uninsured patient, the total cost to the patient is estimated at 
$203.13 for an existing patient and $239.89 for a new patient.  
In comparison, the average cost of treatment for pelvic inflammatory disease per the 
CDC (2017) is $3,202.  Since PID can lead to future complication, such as an increased risk 
of ectopic pregnancy and infertility, the cost of untreated genital Ureaplasma can be an 
economic burden to the patient.  
Project Objectives 
Mission and Vision 
 The mission was an evidenced based project to determine if there was a relationship 
between antibiotic treatment differences and recurrence of symptomatic Ureaplasma. By 
determining a relationship between antibiotic treatment of the female patient and their 
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partner, it allowed the primary researcher to identify patients at risk and prevent further 
disease by proper treatment. The investigator’s vision was to have a standardized testing and 
treatment for patients with a positive genital Ureaplasma spp. culture.  
Goals 
 The goal of this project was to determine whether the relationship between treatment 
differences and recurrence of symptomatic genital Ureaplasma was statistically significant. 
Another goal was to explore the recommendations of evidenced-based guidelines related to 
urethritis and cervicitis caused by Ureaplasma.  
Process/Outcome Objectives 
 The focused outcome objective for this project was to perform a retrospective chart 
review for patients seen in the clinic from 2018 through 2019, in order to measure rates of 
symptomatic recurrence of genital Ureaplasma in the intervention (treating patient and 
partner with antibiotic therapy) and comparison groups (treating the patient alone). This time 
period was selected to give data for a one-year period, in addition to a three- month time 
period for recurring symptoms. The investigator followed a specific project timeline, shown 
in Appendix G, to achieve completion of the project. 
Logic Model 
 A logic model template adapted from Zaccagnini & White (2017) was used to outline 
the target short-term and long-term goals and benchmarks for the investigator (see Appendix 
H). The first step on of the conceptual model, was to establish a close working relationship 
with the DNP clinical mentor and the DNP project chair at Regis University. Developing a 
relationship helped the investigator identify and implement an achievable outline for the 
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project. The Logic Model also helped the investigator determine activities to conduct the 
project with expected outputs.  
Methodology and Evaluation 
QI Project Study Design 
The capstone quality improvement initiative required the investigator to use a non-
experimental quantitative study design using a retrospective chart review. Using a 
retrospective chart review for the project allowed the investigator to have quick and readily 
available access to patient records, allowing less loss of follow up of recurrent symptoms 
(Nickson, 2019). Other advantages of using RCR include providing a cost-effective and 
efficient means to collect (Gregory & Radovinsky, 2012). Disadvantages of a retrospective 
chart review included inconsistent and incomplete or missing entry in the EMR and using a 
convenience sample may not be representative of the general population (Gregory & 
Radovinsky, 2012) 
 The independent variables of the project identified were 1) antibiotic treatment of the 
patient and partner and 2) antibiotic treatment of the patient alone with doxycycline, 
azithromycin, or “other” antibiotic. The dependent variable or outcome was a decrease in the 
incidence of symptomatic recurrence as measured by the difference in means between the 
two groups (patient treated alone versus treatment of patient and partner). Dependent 
variables were identified by 1) test of cure results when both patient or patient and partner are 
treated with antibiotics or 2) resolution of symptoms measured by no return clinical visit for 
symptoms within a 3-month time period.  
Extraneous variables that the researcher encountered was lack of patient follow up for 
a test of cure, co-infections, treating provider that is treating the patient and the choice of 
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antibiotics, patient compliance in completing the antibiotic regime, and form of 
contraception.  
Data Collection and Treatment Procedure 
 The primary investigator followed the steps below when conducting the  
retrospective chart review:  
1) Obtained approval to conduct QI project from Regis University IRB after submitting QI 
Checklist and Summary as well as approval from HCA (for example contracts personnel, 
IT security officer). 
2) The primary investigator was responsible for overseeing data collection by providing 
ICD-10 codes to the clinical mentor to identify patients with positive genital Ureaplasma.  
The clinical mentor was the only one that collected data from the clinic patient EHRs.  
a. Identified ICD-10 codes of symptomatic signs of genital Ureaplasma in female 
patients. 
b. Collected NAAT testing results for genital Ureaplasma spp. 
c. Identified treatment of patient (comparison) versus treatment of patient and 
partner (intervention). 
d. Identified patients that returned for recurrent symptoms of genital Ureaplasma in 
a three-month time period or returned for a test of cure after treatment. 
e. Identified which antibiotic was used for treatment.  
3) Measured the difference between patients that were treated with antibiotics alone 
versus the treatment of the patient and partner.  
4) Shared results of QI project with stakeholders (obstetric/gynecologic providers) after 
the DNP project defense. 
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Population and Sampling Parameters 
 The sample population used for the capstone project included a convenience sample 
of a total of 128 subjects where only the patient was treated with antibiotics or the patient and 
partner were treated with antibiotics between 2018 and 2019. The sampling size was 
calculated using the G*Power software (Department of Psychology, 2019) with the alpha of 
0.05 and power of 0.80.  
The investigator used ICD-10 codes to identify patients that had been seen for 
possible genital Ureaplasma. The ICD-10 codes that were used are: N76.1 (chronic vaginitis), 
R01.2 (pelvic pain), N89.8 (Other specified non-inflammatory disorders of vagina), N93.9 
(abnormal uterine and vaginal bleeding), and N94.1 (dyspareunia) (ICD.codes, 2020).  
Inclusion criteria were: the patient will have a positive PCR testing for Ureaplasma species, 
regardless of co-infections, as well as antibiotic treatment, including azithromycin, 
doxycycline, and clindamycin.  Exclusion criteria included subject’s having an IUD in place 
and not having a current partner for treatment. The reasoning for the exclusion is to eliminate 
the variable of a new partner within the 3-month time frame and the lack of comparison of 
patient and partner treatment versus patient treatment only with the same sexual partner. The 
reason for excluding patients with IUD’s is antibiotics cannot penetrate non-living 
tissue/devices, therefore Ureaplasma can continue to inhabit the IUD device causing 
recurrence of Ureaplasma. Pregnant women are considered a vulnerable population; 
therefore, they were excluded from the project.  
Setting 
The setting for the capstone project was a three clinic, corporate owned obstetrics and 
gynecology office located in three cities in the metro-Denver area. During the period of time 
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that will be used for the retrospective chart review, there were thirteen providers (six 
physicians, three midwives, and four nurse practitioners.  An estimated 1,500-2,000 patient 
visits were documented per month in all three offices.  
 The site since downsized to a midwife clinic with three full-time and one part-time 
certified nurse midwives. Currently, there are approximately 300-400 patient visits per 
month.  The current location, located in Englewood, Colorado, consist of a main medical 
office, as well as a procedure office where ultrasound and colposcopy is performed. The main 
office has six exam rooms and two rooms used for fetal monitoring.  
Study Instrument: Description, Validity and Reliability 
Reliability and validity were essential to validate the project.  The data collection tool 
consisted of the Hologic Aptima Mycoplasma genitalium Assay. The Hologic website 
defines the Aptima Mycoplasma genitalium assay as an in-vitro nucleic acid amplification 
test (NAAT) used as the detection of ribosomal RNA (rRNA) from Mycoplasma and 
Ureaplasma species (Hologic, 2016). The test is able to categorize the microorganisms into 
M. hominis, M.genitalium, Ureaplasma urealyticum, and Ureaplasma parvum.  The test 
results are automatically interpreted by the Panther system Aptima Mycoplasma genitalium 
Assay software.  The software does not quantify the amount of the microorganism present, 
but provides a qualitative measure (presence of genital Ureaplasma per microscopic field) of 
genital Ureaplasma found on the vaginal or endocervical culture. Control testing is run to 
establish validity by completion of an assay calibration, which is valid for up to 48 hours. Per 
Hologic (2016), “one positive calibrator tube and one negative calibrator tube are run in 
duplicate each time a reagent kit is loaded on the Panther system. Software on the Panther 
system alerts the operator when a new calibrator set is required” (p. 17).  
CONSIDERATIONS OF ANTIBIOTIC TREATMENT 23 
 
The data collection tool utilized in this study was created by the investigator and 
content validity was assessed by the clinical mentor. A detailed data dictionary, found in 
Appendix I, defines each datum that will be collected from the EMR. This dictionary served 
as a guide for the chart reviewer to use when using the data collection tool (see Appendix J). 
The investigator used numbers 1-128 to identify participants. The PCR testing, collected 
from NuSwab and ThinPrep media was sent to LabCorp for positive identification of 
Ureaplasma species. Also included on the data table are descriptions for presenting symptoms 
using select ICD-10 codes, treatment of partner.   
Protection of Human Subjects 
 Before seeking approval from the IRB from Regis University, the investigator 
completed the Collaborative Institutional Training Initiative (CITI) courses (Certificate # 
34972066) to ensure participants safety (see Appendix K). A letter of intent was submitted by 
the investigator and was granted approval by HCA Healthcare on March 27, 2020 (see 
Appendix L, HCA Approval Email).  
The primary investigator was responsible for maintaining integrity of the project and 
patient confidentiality. There were minimal to no risk to the patient because the data was 
gathered from existing medical records following the treatment of genital Ureaplasma. In 
order to maintain patient confidentiality, the clinical mentor collected data by using ICD-10 
codes and patient identifiers such as name, date of birth (DOB), address, or medical record 
number were not included in the data collection process.  The clinical mentor already had 
HCA’s permission for remote secure access to the electronic medical records outside of work 
hours (see Appendix M, Data Use Agreement). The clinical mentor collected data over a 
four-week time period. The de-identified data was delivered to the primary investigator via 
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the secure Regis University email system. Once all information was gathered, the investigator 
organized the results on a Microsoft Excel spreadsheet.  
  The results were reported as de-identified, aggregate data.  The clinical mentor and the 
investigator have been in the medical field over 20 years and stayed within compliance of the 
Health Insurance and Portability Accountability Act (U.S. Department of Health and Human 
Services, 2015).  
The investigator sought approval for the QI project with assistance from the Capstone 
Chair. The investigator was granted approval to conduct the project as non-research (QI) 
from the IRB on April 16, 2020 (see Appendix N, IRB Net Board Action Email).  
Data Collection and Statistical Test 
 The investigator used percentage change as the descriptive analysis for the Capstone 
project. Percentage change is a mathematical calculation determining the percentage 
difference between two scores.  The statistical tool was chosen to specifically measure the 
percentage difference between Group A:  Ureaplasma positive patient alone was treated with 
antibiotic therapy and Group B:  Ureaplasma positive patient and partner was treated with 
antibiotic therapy. The investigator also used Kendall’s tau as the inferential statistic. 
Kendall’s tau is a nonparametric, inferential test measuring the correlation between two 
variables (Polit, 2010). 
 There were two levels of data used in the project. Nominal data is the lowest form of 
measurement and can be divided into categories (Polit, 2010). Identified nominal data were 
the antibiotic prescribed to the patient and test of cure findings. The other level of data used 
for the project was ordinal data, which classifies variables relative to the dimension of 
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interest (Polit, 2010). Ordinal data identified were partner treatment with antibiotics and 
recurrence of symptoms.  
Project Findings 
 The investigator asked the clinical mentor to collect data by using a retrospective 
chart review from 2018 through 2019 using a convenience sample of 128 subjects that were 
seen in the clinical setting with positive genital Ureaplasma cultures.  
The results of the data led the investigator to address the PICO statement. In addition, 
the investigator unintentionally identified the recurrence of genital Ureaplasma with and 
without partner treatment and comparing azithromycin, doxycycline, and clindamycin.  
Project Objective  
The primary objective identified was to assess the rate of symptomatic recurrence of 
genital Ureaplasma in the intervention (treating patient and partner with antibiotic therapy) 
and comparison groups (treating the patient alone).  
Statistical Data 
 Pie charts were used to represent the number of cases where the partner was treated 
with antibiotic therapy, antibiotic prescribed, and symptoms of recurrence (Figure 1). 
 The first pie chart represents whether the patient’s partner was treated (n=59, 47%) or 
not treated (n=69, 53%) with antibiotics.  
 The second pie chart identifies the percentage rate of antibiotics prescribed for the 
patient. Doxycycline was prescribed the most out of all the antibiotics, where n=116, 91%. 
Followed by azithromycin (n=9, 7%). Lastly is clindamycin, where it was prescribed to three 
subjects (2%).  
 The last pie chart shows the rate of patient recurrence of symptomatic genital 
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Ureaplasma after initial treatment. Recurrence rate in a three-month period was 46% (n=60). 
The rate of lack of symptoms occurred in 54% (n=60) of the subjects identified.  
Figure 1 
Statistical Pie Charts 
 
All raw data was converted from a “yes/no” format to a numerical format in order to 
use SPSS for this project. When running the data “1” equates to “no,” which included the 
partner not being treated with an antibiotic and recurrence in a three-month timeframe. The 
number “2” identified partner treatment and recurrence of symptoms.  
Test of cure (TOC) was labelled as: 
0=TOC not done 
1=TOC with negative result 
2=TOC with positive result 
The investigator did collect the data for TOC; however, the investigator did not 
analyze data pertaining to this variable as it was not seen as a factor in the recurrence of 
symptomatic genital Ureaplasma.  




The interpretation of the table below recognizes the frequency of recurrent symptoms 
of the patient. In “1” (partner not treated), 53.9% of patients returned for recurrent symptoms 
if their partner was not treated for genital Ureaplasma. In “2,” 46.1% of the patients did not 
return in a three-month period of time for recurrent symptoms. Using the percentage change 
equation, the difference between the two scores is 14.47% (Table 1). 
Table 1 
Partner Treatment and Recurrence Rate 
 
Using Kendall’s tau to measure correlation, the investigator found that there was no 
statistical difference whether the patient’s partner was or was not treated with antibiotic 
therapy and recurrence of symptoms with p<0.05 (Table 2).  
Table 2 
Kendall’s Tau 
Kendall’s Tau (Sig. 2-
tailed) 
Antibiotic Partner Treated TOC Recurrence 
Antibiotic . .292 .862 .190 
Partner Treated .292 . .547 .816 
TOC .862 .547 . .520 
Recurrence .190 .816 .520 . 
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Further data was run using SPSS for nominal and ordinal levels of collected. 
Unintentional findings of antibiotic effectiveness of patient treatment versus patient and 
partner treatment were analyzed as the investigator and statistical mentor used the percentage 
change (see Table 3).  
Using the percentage change mathematical equation, the investigator found that when 
the patient was treated with azithromycin (n=9) and the partner was not treated, there was a 
50.07% recurrence rate of symptomatic Ureaplasma. The exact same percentage of the 
recurrence rate applies if both the patient and partner were treated with azithromycin, 
If the patient was treated with doxycycline (n=116), and the partner was not treated 
with antibiotics, the rate of recurrent symptoms was 20.47%. If both the patient and the 
partner were treated with doxycycline, the rate of symptomatic recurrence drops to 16.59% 
(Table 3). 
Only three patients received Clindamycin and all three patients had a symptomatic 
recurrence regardless if the partner was treated or not. Comparing the antibiotic treatment, the 
results show the antibiotic of choice at this obstetric-gynecological practice was doxycycline 
for symptomatic genital Ureaplasma, with azithromycin as a secondary choice. The findings 
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Table 3 
Evaluating Partner Treatment, Antibiotic, and Recurrence 
 
 
Limitations, Recommendations, and Implications 
Limitations 
 Limitations of this study included a small sample size and a single area in Colorado, 
therefore the findings cannot be applied to the general population. Another limitation noted 
are the number of subjects that were prescribed doxycycline were at a higher rate than 
azithromycin and clindamycin. A third limitation identified is the lack of interrater reliability 
with the collection tool. Lastly, the project did not include pregnant women or include 
contraception measures. In the clinical setting, it was noted that women with IUD’s had 
recurrent symptoms of genital Ureaplasma whether the partner was treated or not treated with 
antibiotics.  
Recommendations 
 The investigator recommends using a larger sample size to test for statistical 
significance of the treatment of the partner for genital Ureaplasma as per the current CDC 
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guidelines. The investigator also recommends a follow-up project to assess the use of 
doxycycline only to identify recurrence rate with the larger sample size. Lastly, the 
investigator recommends a project addressing IUD’s and recurrence of genital Mycoplasma.   
Polymer implants have been associated with infections resulting from bacteria and biofilm 
adhesion to an implant surface. Ribeiro et al., 2012 noted that once biofilm bacteria inhabit 
the implant, there is a high resistance to conventional antibiotics therapy.  
Implications 
While this study did not generate new phenomenon, the antibiotic findings were 
consistent with CDC guidelines. It appears that doxycycline has a higher success rate for 
treatment of genital Ureaplasma.  
The results showed there was not a statistical improvement of recurrence of genital 
Ureaplasma, however;  there was improvement of 14.47% between patient partner versus 
patient and partner treatment. Therefore, even though not statistically significant, 
consideration to clinical significance when looking at percent change can be significant in 
terms of cost and quality of life to the patient. When presenting to the stakeholders, the 
investigator will recommend a trial study in which both patient and partner are treated with 
antibiotic therapy and analyze the results using the percentage differences to identify if 
there is a further decrease in recurrence.  
Summary 
The proposed quality improvement project is specific to three metro-Denver area 
outpatient obstetrics and gynecology offices owned by a national corporation. The 
investigator explored the use of evidence-based guidelines related to treatment of female 
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patients with a positive genital Ureaplasma culture identified by PCR testing, with and 
without partner treatment. 
 The investigator addressed the PICO question for this project by using a retrospective 
chart review and a percentage difference for descriptive analysis. Even though the 
investigator did not find statistical significance between patient and patient and partner 
antibiotic treatment and recurrent Ureaplasma, the investigator observed a possible 
relationship between recurrent symptoms and the prescribed antibiotic. Further studies would 
be indicated based on the clinical considerations to the patient’s quality of life and partner 
treatment for symptomatic genital Ureaplasma. The clinical importance of the study, though 
not statistically significant, support the CDC guidelines of patient treatment of genital 
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Appendix B 
Lewin’s Theory of Change 
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Appendix C 
Literature Review Example 
 
Article Title and 
Journal 
Susceptibility and antimicrobial resistance of genital ureaplasma 
parvum.  Nano Biomedicine and Engineering, 9 (3), 236-241.     
Author/Year Al-Khadfaji, G. K. (2017). 
Database and 
Keywords Database: Ovid. Keywords: Genital and ureaplasma 
Research Design Quasi-experimental 
Level of Evidence Level III 
Study Aim/Purpose 
Investigating the antimicrobial susceptibility of Ureaplasma 









1)Fixed amount of Ureaplasma parvum was cultured in broth 
medium in sterile test tubes. 2) Concentrations were numbered 
for addition of each antibiotic and stored at 37 Celsius x 48hours 
3) Agar medium was then inoculated and stored at 37 Celsius x 
24 hours 4) Amount of bacterial growth was then analyzed.  
Primary Outcome 
Measures and Results 
80% of Ureaplasma parvum isolates were susceptible to 
doxycycline at the highest with 0% susceptible to gentamycin and 
azithromycin. 
Author Conclusions/ 
Implications of Key 
Findings 
For treatment of Ureaplasma parvum, doxycycline (80% 
susceptible), clarithromycin (71.4% susceptible), and 
levofloxacin (65.7% susceptible) should be the antibiotics of 
choice. 
Strengths/ Limitations 
Strengths: controlled environment of test tubes and culture 
growth. Susceptibility was performed using 6 different 
antibiotics.   Limitation: Small sample size, no mention of how 
collection of Ureaplasma parvum was obtained, and presence of 
the growth of bacteria was measured by turbidity only.  
Funding Source None listed 
Comments 
Erythromycin was recommended for treatment during pregnancy, 
which has a 42% susceptibility rate.  





• Evidenced based practice and 
guidelines supported by the 
systematic review of literature 
 
•  Favorable Nucleic Acid 
Amplification Tests (NAAT) readily 
available in the clinical setting   
 
 
• Clinical support from providers for a 
quality initiative project  
 
Weaknesses 
• Investigator is no longer employed 
at the site the capstone project 
 
• Capstone site is now a midwife-only 




• Potential resistance to change 
provider practice of treatment of 
genital Ureaplasma 
 
• Data collection is limited to one area 
located in the metro-Denver area 
Opportunities 
• Provide evidenced based literature 
review and guidelines to existing 
providers 
 
• Providing information of NAAT 
collection to identify Ureaplasma 
 
 
• Decrease future obstetrical and 
gynecologic morbidities caused by 
genital Ureaplasma 
 
•   Decrease the overall cost to health 
insurance companies and the patient  




• Unstable state of the corporate run 
clinic 
 
• Remaining five providers may not 
be able to attend the QI presentation 
resulting in providers continuing to 









Budget and Resources 
 
Items Cost Cost to Replicate 
Investigator Time: $50/hour x 
80 hours 
$0 $4,000 






NAAT (Thin prep, 500 count) $0 $2750* 
G*Power Software (free 
download) 
$0 $0 
Total $0 $8,925 




• Patients  
• Clinical mentor  
• Capstone chair  
 
Time:  

























Letter of Intent 
 
DNP Quality Improvement Project Letter of Intent 
To: Laura Collison 
From: Shelbie Paul  
Subject: DNP Project 
Date: December 11, 2019 
I am writing to obtain permission to conduct a quality improvement (QI) project in your 
facility (Mountain Vista Midwifery) with the purpose of using a retropective chart review 
study design to investigate if there is a difference in the incidence of symptomatic recurrence 
of genital Ureaplasma in the female patient, when treating the patient and partner as 
compared to treating the patient alone with antibiotics.  This project will be done to fullfill 
requirements for completion of the Doctor of Nursing Practice degree at Regis University, 
Denver, CO.  The following information will review the study: 
This project will employ a Population-Intervention-Comparative-Outcome (PICO) 
format for development of the DNP project question to be investigated: 
Population: Women with symptomatic genital Ureaplasma 
Intervention: Treating patient and partner with antibiotic therapy 
Comparative: Treating the patient alone 
Outcome: Decrease in the incidence of symptomatic recurrence of genital Ureaplasma 
Quality Improvement Project Question: Do women with symptomatic genital 
Ureaplasma have a decreased incidence of symptomatic recurrence when both the patient 
and the partner are treated with antibiotic therapy than treatment of the patient alone?   
Project Significance: Untreated, genital Ureaplasma can lead to pelvic inflammatory 
disease, infertility, premature rupture of membranes, preterm delivery, and infection in the 
neonate (Verteramo et al., 2013).  
The Centers for Disease Control and Prevention (CDC, 2015) recommends treatment with 
azithromycin and doxycycline; however, the efficacy of azithromycin is declining. Women 
treated for cervicitis, should abstain from intercourse until their partners have completed 
treatment with antibiotic therapy. 
Findings in this QI project may support the creation of a standard approach based on the 
CDC guidelines in managing the care of women with symptomatic Ureaplasma. 
 
Type of Quality Improvement Project Study Design: A retrospective chart review using a 
convenience sample 
Participant Requirement: None, as the data collected already exists in the chart. While 
conducting the retrospective chart review, I will be working with my clinical mentor, Shana 
Martin, CNM, in using ICD 10 codes to identify the diagnosis of Ureaplasma, and its 
treatment and recurrence. 
Risks, Cost, and Benefits:  
• Risks: Risks are minimal to none for the participants. The project will use existing data in 
the electronic health record. Data collected will be de-identified. I will submit an 
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application to the Regis University IRB and HealthOne IRB (if required) prior to 
conducting this quality improvement project. 
• Costs: The cost will be minimal to none to conduct the retrospective chart review.  
• Benefits:  If all providers treat the patient and partner, there may be a decrease in cost to 
the insurance company and patient related to long-term issues caused by genital 
Ureaplasma pathogens.  
Project Goals and Objectives: 
The main goal of this project is to explore if there is a difference in the incidence of 
symptomatic recurrence of genital Ureaplasma based on two treatment modalities; treating 
the patient only or treating the patient and partner with antibiotics.  
Objectives: 
1. Identify symptoms of vaginitis 
2. Identify antibiotic treatment 
3. Identify if the patient alone or the patient and partner were treated for Ureaplasma. 
4. Measure rates of symptomatic recurrence of genital Ureaplasma in the intervention 
and comparison groups 
5. After DNP Capstone defense, share results of QI project with leadership at site of 
study 
Permission is requested to conduct this quality improvement project at Mountain Vista 
Midwifery located at 701 E. Hampden Ave. Suite 110 Englewood, CO 80113.  
I have included a template for the brief site approval letter that is required on letterhead from 
you. 
Thank you for your assistance with completing my DNP Quality Improvement Project. 
 
Sincerely, 




















































 Constraints Activities Outputs Short term Long term Impact 
Personnel Establish working 
relationship with project 




providers that are testing 
for Ureaplasma  
 





Training providers to 




















treatment of patient 





patient for testing 
(pelvic pain, 
reoccurrence of 













to providers  
Develop 
consistency of 











patient on the 
first visit that 
should be tested 






Financial Lab costs to patient 
depending on insurance 
coverage 
 




Cost of antibiotics 
for the patient 
Decrease cost of 





number of visits 
for patients for 
recurrent 
symptoms 
Time IRB approval time 
 
Time Restraint 








that return to the 







of patient vs 
treatment of patient 




Time lapse between 
positive culture, 
calling and treating 
patient and partner 
Course of 
antibiotic 
treatment (7 days) 
Not identified Not identified 








antibiotics (verbal or 




taking full course 
of antibiotics 
Not identified Not identified 
Equipment Electronic Health 
Records downtime, lack 




HER None None None 




HCA clinic services Not identified Not identified Not identified HCA clinic 
services  
Adapted from “The Doctor of Nursing Practice Essentials,” by M. E. Zaccagnini and K. W. White, 2017.   
 






NAME          DESCRIPTION      FORMAT 
 









NAAT testing: NuSwab or 
Thinprep (PCR: polymerase 
chain reaction) 
Positive or negative Nucleic Acid Amplification Test 
collected form the endocervical 
canal/vaginally. 
PCR will be resulted as 
“positive” or “negative” and 
identify Ureaplasma species. 
Subject Numeric identification A number between1-128 will be 
assigned to each subject 
Test site N/A Healthone clinic services 
Presenting symptoms ICD-10 codes N76.1 (chronic vaginitis) 
R01.2 (pelvic pain) 
N89.8 (Other specified non-
inflammatory disorders of 
vagina) 
N93.9 (abnormal uterine and 
vaginal bleeding) 
N94.1 (dyspareunia) 
Treatment of partner Yes or no Telephone encounters to patients 
will need to be looked at to see if 
the partner was treated or not 




Type of antibiotic used will be 
identified 
TOC on follow-up visit  Positive, negative, not done NAAT test results after 
completion of antibiotic therapy 
(8-21 days) 
Recurrence in 3-month period 
(Y/N) 
See ICD-10 “Presenting 
symtoms” 
NAAT test with positive results 



























in 3 Month 
Period 
(Y/N) 
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Data Use Agreement 
 
DATA USE AGREEMENT 
This Agreement is entered into as of March 26, 2020 (the "Effective Date"), by and 
between Mountain Vista Midwifery ("Practice") and Shelbie Paul ("User"). User is pursuing a 
Doctor of Nursing Practice degree at Regis University and desires to access certain patient-
related data of Practice for research required in order to complete such degree. In connection 
therewith, the parties wish to exchange a limited data set as permitted by the HIPAA Privacy 
Rules (45 CFR Part 160 and Part 164, Subparts A and E) for research purposes in accordance 
with the terms and conditions set forth in this Agreement. In consideration of the mutual 
promises hereinafter recited, the parties hereto agree as follows: 
1. Definitions. Limited Data Set shall have the same meaning as the term "limited data set" in 
45 C.F.R. §164.512(e)(2), as amended from time to time. Any remaining terms used, but 
not otherwise dermed, in this Agreement, shall have the same meaning as those terms in 
the HIPAA Privacy Rule, as amended from time to time. 
2. Permitted Uses and Disclosures. Practice will provide data as described on Exhibit A 
("Data") to User. The Data will constitute a Limited Data Set. User agrees to only use the 
Data for the purposes of the research described on Exhibit A consistent with the HIPAA 
Privacy Rule. User shall not disclose the Data to any third party unless agreed in writing in 
advance by Practice or unless the Data has been further de-identified so that it complies with 
the de-identification safe harbor set forth at 45 CFR §164.514(b), which among other things 
requires that any dates or portions of dates (other than year) be removed, including dates of 
service. 
3. Other Obligations. User will 
a. only use and disclose the Data as permitted by this Agreement or as Required By 
Law; 
b. use appropriate safeguards to prevent use or disclosure of the Data other than as 
provided for by this Agreement; 
c. report to Practice in writing immediately any use or disclosure of the Data not 
provided for by this Agreement of which User becomes aware; 
d. ensure that any Subcontractors or agents to whom User provides the Data agree to 
the same restrictions and conditions that apply to User with respect to such 
information; and 
e. not identify or attempt to identify the Data nor contact or attempt to contact the 
individuals who are the subject of the Data. 
4. Term. This Agreement shall be effective as of the Effective Date and remain in effect until 
terminated by either party or one year from the Effective Date, whichever is earlier. Either 
1 
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party may terminate this Agreement upon thirty (30) days' written notice to the other party. 
Upon termination of this Agreement, User shall destroy the Data if feasible. User's 
obligations set forth in Sections 2 through 3 shall survive any termination of this 
Agreement for so long as User maintains any of the Data. 
5. Notice. All notices and other communications required or permitted to be given shall be 
made in writing and shall be considered given and received when deposited in the United 
States mail, postage prepaid, return receipt requested and addressed as set forth below or 
at such other address such party shall have specified by notice given in accordance with 
the provisions of this Section: 
 
If to PRACTICE, to: If to USER, to: 
Mountain Vista Midwifery 
701 E. Hampden Ave, 
Suite 110 Englewood, CO 
80113 
Attn: Shana Martin 
6. Confidentiality. User acknowledges that information regarding Practice's business 
operations, including, but not limited to, procedures, programs, formularies and 
reimbursement schedules are proprietary and confidential, and agrees to hold such 
information in strict confidence and not to disclose or make available such information to 
any third party, except as required by law. This provision shall survive termination of this 
Agreement. 
7. Miscellaneous. None of the provisions of this Agreement are intended to create any 
relationship between the parties other than that of independent entities contracting with each 
other solely for the purpose of effecting the provisions of this Agreement. The parties agree to 
amend this Agreement as necessary to comply with the HIPAA Privacy Rule and other 
applicable law. This Agreement constitutes the entire written agreement of the parties with 
respect to the subject matter of this Agreement and supersedes any prior written agreements 
of the parties regarding the subject matter of this Agreement. Any ambiguity in this Agreement 
shall be resolved to permit Practice to comply with the HIPAA Privacy Rule. Nothing in this 
Agreement shall confer upon any person other than the parties and their respective successors 
or assigns, any rights, remedies, obligations, or liabilities, whatsoever. 
IN WITNESS WHEREOF, the parties have executed this Agreement as of the date 
and year first above written. 
USER: 
B Y :  





Title: Vice President 
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EXHIBIT A  
The Data consists of the following: 
• ICD-10 Visit Code 
• results of culture 
• antibiotic prescribed 
• partner treated (yes/no) 
• TOC/recurrence in 3 month period 
Practice will collect data that will constitute a Limited Data Set from its records and 
provide the Data to User. The Data is provided for the following research project which 
involves collecting data from medical charts on a retrospective basis. User certifies that 
the description of the research project set forth below is accurate and complete. 
This project will employ a Population-Intervention-Comparative-Outcome (PICO) format 
for development of the doctor of nurse practice project question to be investigated: 
Population: Women with symptomatic genital Ureaplasma 
Intervention: Treating patient and partner with antibiotic therapy 
Comparative: Treating the patient alone 
Outcome: Decrease the incidence of symptomatic recurrence of 
genital Ureaplasma 
Quality Improvement Project Question: Do women with symptomatic genital 
Ureaplasma have a decreased incidence of symptomatic recurrence when both the 
patient and the partner are treated with antibiotic therapy than treatment of the 
patient alone? 
Project Title: Considerations of antibiotic treatment for genital Ureaplasma. 
Project Significance: Untreated, genital Ureaplasma can lead to pelvic 
inflammatory disease, infertility, premature rupture of membranes, preterm 
delivery, and infection in the neonate. 
Type of Quality Improvement Project Study Design: Retrospective 
Participant Requirement: None. User will receive Data from Practice. 
Risks, Cost, and Benefits: If all providers treat the patient and partner, there will 
be a decrease in cost to the insurance company and patient related to long-term 
issues caused by genital Ureaplasma pathogens. 
Project Goals and Objectives: The main goal of this project is to apply standard of 
care to women with symptomatic Ureaplasma. 
Objectives: 
3 
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1. Identify symptoms of genital Ureaplasma species. 
2. Identify antibiotic treatment. 
3. Identify if the patient alone or the patient and partner were treated  
for Ureaplasma. 
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